InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Discover the full record of transactions filed by Snyder Mark Howard. Director active across 1 company, notably Halozyme Therapeutics, INC.. Aggregated, 10 disclosures have been logged. Activity tracked since 3 January 2023. The latest transaction was disclosed on 20 February 2026 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations
Snyder Mark Howard is SVP, CHIEF LEGAL OFFICER at Halozyme Therapeutics, INC. He has 10 filings in total, and among the 10 sampled filings the period runs from 2023-01-04 to 2026-02-24. The most frequent transaction nature is Option exercise, and the buy and sell amounts are EUR 0 and EUR 0.